News

City of San Antonio enacting plan to better leverage military medical assets

  The San Antonio Military Life Science Commercialization Action Plan seeks to better leverage ...

Rapamycin Holdings Treats First Humans in eRapa Clinical Trial

Featured image is of SwRI staff working in their cGMP clean room where clinical supplies of their ...

Events

Learn to Prepare IND for Small Molecule Drugs

How does a drug development program evolve from a brilliant research idea? Join Southwest Research Institute ...
News
Texas Biomed Is Part Of A Team Of Scientists Awarded $5.4 Million By The National Institutes Of Health To Develop Hemorrhagic Fever Vaccines
May 2, 2011

 

 

 

 

SAN ANTONIO, May 2, 2011 - The National Institutes of Health has awarded nearly $5.4 million to a collaborative team of scientists at the Texas Biomedical Research Institute, Emory University, and Georgia Institute of Technology to develop vaccines for prevention of deadly hemorrhagic fevers.

The project focuses on the development of an effective vaccine for Ebola and Marburg virus infections, two members of a family named "filoviruses" because they produce long filamentous particles. Both viruses are considered potential bioterrorism threats. The vaccines will be tested in Texas Biomed's high containment laboratories.

The lead investigators include Texas Biomed's Jean L. Patterson, Ph.D., and Ricardo Carrion Jr., Ph.D.; Richard Compans, Ph.D., and Chinglai Yang, Ph.D., at Emory University; and Mark Prausnitz, Ph.D., at Georgia Tech.

"Our experience and expertise in select agent research, and in vaccine pre-clinical development, as well as with the Ebola virus itself is one of the reasons this project was successfully funded," said Patterson, who chairs the Institute's Department of Virology and Immunology.

"This award underscores the important international role played by Texas Biomed," said Kenneth P. Trevett, the Institute's president and CEO.

The Emory group has developed virus-like particle (VLP) vaccines to prevent virus infection, and has shown that the Ebola VLPs stimulate immune cell activity and induce strong antibody responses, indicating that such VLPs could be effective vaccines to induce protective immunity against infection. They also have found that immunization with a mixture of DNA and VLP vaccines induced higher levels of protective immune responses in comparison to immunization with either vaccine alone.

"We consider this to be one of the most promising and safest approaches to protecting against hemorrhagic fever viruses," added Patterson.

Texas Biomed, formerly the Southwest Foundation for Biomedical Research, is one of the world's leading independent biomedical research institutions dedicated to advancing health worldwide through innovative biomedical research. Located on a 200-acre campus on the northwest side of San Antonio, Texas, the Institute partners with hundreds of researchers and institutions around the world to develop vaccines and therapeutics against viral pathogens causing AIDS, hepatitis, herpes, hemorrhagic fevers, and a host of other illnesses. The Institute also has programs in the genetics of cardiovascular disease, diabetes, obesity, psychiatric disorders and other diseases. For more information on Texas Biomed, go to www.TxBiomed.org.

 

Stay informed. Subscribe to BioMed SA news alerts.